Larry Rubinstein

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I

  JCO Precision Oncology · 2026-06-01

• A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors

  Cancer Chemotherapy and Pharmacology · 2025-12-22

• Data from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Table 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Figure 3 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Figure 2 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Figure 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Table 2 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Data 1 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Table 3 from Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  2025-12-01

• Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in <i>CCND1</i>, <i>2</i>, or <i>3</i> Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

  2025-11-25

• Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i> -Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T

  JCO Precision Oncology · 2025-10-01

• 1709MO Multi-center NCI-sponsored phase I study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

  Annals of Oncology · 2025-09-01 · 1 citations

• PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P

  JCO Precision Oncology · 2025-08-01 · 1 citations

• Risk Factors for COVID-19–Related Hospitalization and Death in Patients With Cancer

  JAMA Oncology · 2025-07-17 · 6 citations

• Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia–Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors

  JCO Precision Oncology · 2025-07-01 · 2 citations

• Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

  Clinical Cancer Research · 2025-06-27 · 4 citations

• Supplementary Table S9 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors

  2025-06-03

• Supplementary Table S7 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors

  2025-06-03

• Supplementary Table S1 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors

  2025-06-03